StockDrifts LogoStockDrifts

Meditor Group 13F Portfolio

Portfolio Manager
Meditor Group Ltd
Performance
0% (N/A)
AUM (13F)
$48.15M
# of Holdings
4
Performance Rank
N/A
Allocation (Top 20)
N/A
Latest filing
Q3 2024

Meditor Group Ltd Holdings Map

Top 4 Meditor Group Ltd Holdings

Top 10 holdings

StockCompany% Port.SharesValueActivityOwnershipAvg. CostDate
EXEL
EXELIXIS INC
73.43%1.36M$35.4M
-22.28%(-390.55K)
2023-Q3: 3.14M shares2023-Q4: 2.64M shares2024-Q1: 2.20M shares2024-Q2: 1.75M shares2024-Q3: 1.36M shares2024-09-30
ESPR
ESPERION THERAPEUTICS INC
12.99%3.79M$6.3M
+0.00%(+0)
2023-Q3: 3.79M shares2023-Q4: 3.79M shares2024-Q1: 3.79M shares2024-Q2: 3.79M shares2024-Q3: 3.79M shares2024-09-30
INDA
ISHARES MSCI INDIA ETF
7.22%59.4K$3.5M
+0.00%(+0)
2023-Q3: 59.4K shares2023-Q4: 59.4K shares2024-Q1: 59.4K shares2024-Q2: 59.4K shares2024-Q3: 59.4K shares2024-09-30
EPI
WISDOMTREE INDIA EARNINGS FUND
6.36%60.7K$3.1M
+0.00%(+0)
2023-Q3: 60.7K shares2023-Q4: 60.7K shares2024-Q1: 60.7K shares2024-Q2: 60.7K shares2024-Q3: 60.7K shares2024-09-30

About Meditor Group Ltd’s portfolio

Meditor Group Ltd reports $48.15M in US-listed equity holdings across 4 positions in its most recent 13F filing. Its largest disclosed positions are EXEL (73.4%), ESPR (13.0%) and INDA (7.2%). Figures reflect the Q3 2024 filing.

Portfolio concentration

Portfolio concentration
EXEL — 73.4% ($35.36M)ESPR — 13.0% ($6.26M)INDA — 7.2% ($3.47M)EPI — 6.4% ($3.06M)
100%in top 4
  • EXEL73.4%
  • ESPR13.0%
  • INDA7.2%
  • EPI6.4%

Portfolio changes

What the fund actually did

Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.

Trimmed
1
EXELEXELIXIS INC-22.3%

Unlock alerts, watchlists & AI chat

Sign up free to track Meditor Group Ltd, compare funds side by side, and get alerts the moment positions change.

Source filings

Holdings on this page are parsed from Meditor Group Ltd’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1382333). View Meditor Group Ltd’s 13F filings on SEC

More 13F analyses

View all